Novo-CSO: It’s a setback, we have to admit it
It is a setback – but no catstrophe – for Novo Nordisk that Tresiba failed to win approval in the US, the company’s CSO says. He points out that a pre-approval study will be less extensive and expensive than a post-approval study.
by Kresten Morten Munksgaard
It is a major setback for Novo Nordisk in the battle for control of the market for long-acting insulin that Tresiba is not set to hit the US market for some time to come now, Novo’s Chief Science Officer, Mads Krogsgaard Thomsen, admits to Medwatch.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler:
Tresiba all set for Japanese launch
For abonnenter
Analyst: It is a massive surprise
For abonnenter
FDA denies application for Tresiba and Ryzodeg
For abonnenter
.jpg&w=384&q=75)
